IDT Australia Limited researches, develops, manufactures, and sells active pharmaceutical ingredients (APIs) and finished dose form products in Australia and internationally.
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$0.58|
|52 Week High||AU$0.15|
|52 Week Low||AU$0.76|
|1 Month Change||-1.70%|
|3 Month Change||78.46%|
|1 Year Change||286.67%|
|3 Year Change||262.50%|
|5 Year Change||176.19%|
|Change since IPO||271.25%|
Recent News & Updates
IDT Australia's (ASX:IDT) Promising Earnings May Rest On Soft Foundations
Investors were disappointed with IDT Australia Limited's ( ASX:IDT ) earnings, despite the strong profit numbers. We...
Is IDT Australia's (ASX:IDT) 280% Share Price Increase Well Justified?
It might seem bad, but the worst that can happen when you buy a stock (without leverage) is that its share price goes...
IDT Australia (ASX:IDT) Is In A Good Position To Deliver On Growth Plans
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Does IDT Australia's (ASX:IDT) CEO Salary Compare Well With The Performance Of The Company?
David Sparling has been the CEO of IDT Australia Limited ( ASX:IDT ) since 2018, and this article will examine the...
|IDT||AU Pharmaceuticals||AU Market|
Return vs Industry: IDT exceeded the Australian Pharmaceuticals industry which returned -2.4% over the past year.
Return vs Market: IDT exceeded the Australian Market which returned 20.2% over the past year.
Stable Share Price: IDT is more volatile than 90% of Australian stocks over the past 3 months, typically moving +/- 16% a week.
Volatility Over Time: IDT's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of Australian stocks.
About the Company
IDT Australia Limited researches, develops, manufactures, and sells active pharmaceutical ingredients (APIs) and finished dose form products in Australia and internationally. The company offers analytical method development, stability chambers, and chemistry and microbiology quality control laboratory services. Its services also include project management, chemical, analytical chemistry, pharmacy, clinical packaging, and regulatory affairs, as well as pharmaceutical development services in all dosage forms.
IDT Australia Fundamentals Summary
|IDT fundamental statistics|
Is IDT overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|IDT income statement (TTM)|
|Cost of Revenue||AU$1.87m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||0.0088|
|Net Profit Margin||12.42%|
How did IDT perform over the long term?See historical performance and comparison
Is IDT Australia undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate IDT's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate IDT's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: IDT is poor value based on its PE Ratio (66.2x) compared to the Oceanic Pharmaceuticals industry average (45x).
PE vs Market: IDT is poor value based on its PE Ratio (66.2x) compared to the Australian market (19.8x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate IDT's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: IDT is overvalued based on its PB Ratio (5x) compared to the AU Pharmaceuticals industry average (3.3x).
How is IDT Australia forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as IDT Australia has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has IDT Australia performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: IDT has high quality earnings.
Growing Profit Margin: IDT became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: IDT has become profitable over the past 5 years, growing earnings by 37.7% per year.
Accelerating Growth: IDT has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: IDT has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (17.4%).
Return on Equity
High ROE: IDT's Return on Equity (7.6%) is considered low.
How is IDT Australia's financial position?
Financial Position Analysis
Short Term Liabilities: IDT's short term assets (A$17.3M) exceed its short term liabilities (A$6.1M).
Long Term Liabilities: IDT's short term assets (A$17.3M) exceed its long term liabilities (A$445.0K).
Debt to Equity History and Analysis
Debt Level: IDT's debt to equity ratio (2.8%) is considered satisfactory.
Reducing Debt: IDT's debt to equity ratio has reduced from 5.8% to 2.8% over the past 5 years.
Debt Coverage: IDT's debt is well covered by operating cash flow (48.3%).
Interest Coverage: IDT's interest payments on its debt are well covered by EBIT (62.3x coverage).
What is IDT Australia current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate IDT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate IDT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if IDT's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if IDT's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: IDT is not paying a notable dividend for the Australian market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of IDT's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Dr. David Sparling, BVSc (Hons), LLB (Hons), GDipAppCGov, has been the Chief Executive Officer at IDT Australia Limited since July 2018 and previously served as its Interim Chief Executive Officer since Fe...
CEO Compensation Analysis
Compensation vs Market: David's total compensation ($USD445.70K) is above average for companies of similar size in the Australian market ($USD302.72K).
Compensation vs Earnings: David's compensation has been consistent with company performance over the past year.
Experienced Management: IDT's management team is considered experienced (2.5 years average tenure).
Experienced Board: IDT's board of directors are considered experienced (4.1 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
IDT Australia Limited's employee growth, exchange listings and data sources
- Name: IDT Australia Limited
- Ticker: IDT
- Exchange: ASX
- Founded: 1975
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: AU$147.514m
- Shares outstanding: 239.86m
- Website: https://en.idtaus.com.au
- IDT Australia Limited
- 45 Wadhurst Drive
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/18 07:04|
|End of Day Share Price||2021/10/18 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.